| Patent application number | Description | Published |
|---|
| 20080214556 | USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES - Disclosed are methods for treating patients suffering from cardiovascular diseases comprising administering an intravenous (IV) infusion of ranolazine. In one embodiment, the IV infusion of ranolazine is followed by an orally administered sustained release ranolazine dosage formulation to maintain human ranolazine plasma levels at therapeutic levels in patients. | 09-04-2008 |
| 20080233191 | USE OF RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE - This invention is directed to the use of ranolazine to reduce the risk of adverse coronary events in a mammalian patient. Typically, the natriuretic peptide is associated with coronary disease, acute coronary syndrome, and/or diastolic dysfunction. Ranolazine may be administered to the patient as an intravenous solution or in an oral dose. | 09-25-2008 |
| 20080248112 | USE OF RANOLAZINE FOR THE TREATMENT OF CORONARY MICROVASCULAR DISEASES - Disclosed are methods for treating patients suffering from coronary microvascular disease comprising administering ranolazine to the patient. In one embodiment, ranolazine is administered as an oral dose | 10-09-2008 |
| 20080299195 | USE OF RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE - This invention is directed to the use of ranolazine to reduce the risk of adverse coronary events in a mammalian patient. Typically, the natriuretic peptide is associated with coronary disease, acute coronary syndrome, and/or diastolic dysfunction. Ranolazine may be administered to the patient as an intravenous solution or in an oral dose. | 12-04-2008 |
| 20090111826 | USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES - Disclosed are methods for treating patients suffering from cardiovascular diseases comprising administering an intravenous (IV) infusion of ranolazine. In one embodiment, the IV infusion of ranolazine is followed by an orally administered sustained release ranolazine dosage formulation to maintain human ranolazine plasma levels at therapeutic levels in patients. | 04-30-2009 |
| 20090312340 | USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES - Disclosed are methods for treating patients suffering from cardiovascular diseases comprising administering an intravenous (IV) infusion of ranolazine. In one embodiment, the IV infusion of ranolazine is followed by an orally administered sustained release ranolazine dosage formulation to maintain human ranolazine plasma levels at therapeutic levels in patients. | 12-17-2009 |
| 20100035890 | USE OF RANOLAZINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES - Disclosed are methods for treating patients suffering from cardiovascular diseases comprising administering an intravenous (IV) infusion of ranolazine. In one embodiment, the IV infusion of ranolazine is followed by an orally administered sustained release ranolazine dosage formulation to maintain human ranolazine plasma levels at therapeutic levels in patients. | 02-11-2010 |
| 20100197701 | METHOD OF TREATING DIABETES - Methods are provided for treating diabetes, lowering plasma level of HbA1c, glucose plasma levels, total cholesterol plasma level, and/or triglyceride plasma level while increasing HDL cholesterol levels and delaying onset of diabetic retinopathy in a diabetic, pre-diabetic, or non-diabetic mammal while minimizing undesirable side effects. | 08-05-2010 |
